奥希替尼靶向治疗对晚期非小细胞肺癌患者近远期生存的影响  

Effect of Ohitinib Targeted Therapy on Near and Long Term Survival in Patients with Advanced Non-small Cell Lung Cancer

作　　者：伍松松 虞希祥 WU Songsong;YU Xixiang(Department of Radiation Oncology,the Third Afiliated Hospital of Wenzhou Medical University,Wenzhou 325200,Zhejiang,China;Department of Intervention,Wenzhou Third Clinical College,Wenzhou Medical University,Wenzhou 325000,Zhejiang,China)

机构地区：[1]温州医科大学附属第三医院肿瘤放疗科,浙江温州325200 [2]温州医科大学温州市第三临床学院介人科,浙江温州325000

出　　处：《中国药物滥用防治杂志》2023年第5期828-831,共4页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：瑞安市科技计划项目(编号:MS2020003)。

摘　　要：目的:探讨奥希替尼靶向治疗对晚期非小细胞肺癌患者近远期生存的影响.方法:回顾性分析2018年10月—2020年9月温州医科大学附属第三医院收治的晚期非小细胞肺癌患者117例,将使用培美曲塞^(+)顺铂化疗方案的54例患者纳入对照组,将使用奥希替尼联合培美曲塞^(+)顺铂化疗方案的63例患者纳入观察组.所有患者均连续治疗12周,治疗结束后均随访5~12个月.比较两组临床疗效、肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白21片段抗原(Cyfra21-1)]、不良反应发生率及随访期间无进展生存期(PFS)与总生存期(OS).结果:观察组总有效率高于对照组(P<0.05);观察组CEA、CA125、Cyfra21-1水平低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);随访期间,观察组中位PFS、中位OS均高于对照组(P<0.05).结论:奥希替尼靶向治疗联合化疗能有效提高晚期非小细胞肺癌近远期疗效,具有一定安全性,临床应用价值高.Objective:To investigate the effects of ohitinib targeted therapy on the near and long term survival of patients with advanced non-small cell lung cancer.Methods:A total of 117 patients with advanced non-small cell lung cancer admitted to the Third Affiliated Hospital of Wenzhou Medical University from October 2018 to September 2020 were retrospectively analyzed.Fifty-four patients treated with pemetrexed and cisplatin chemotherapy were included in the control group,and 63 patients treated with osimertinib combined with pemetrexed and cisplatin chemotherapy were included in the observation group.All patients were treated for 12 weeks and followed up for 5-12 months after treatment.The clinical efficacy,tumor markers carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 21 fragment antigen(Cyfra21-1),incidence of adverse reactions,progression-free survival(PFS)and overall survival(OS)during follow-up were compared between the two groups.Results:The total effective rate of the observation group was higher than that of the control group(P<0.05).The levels of CEA,CA125 and Cyfra21-1 in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).During the follow-up period,the median PFS and median OS of the observation group were higher than those of the control group(P<0.05).Conclusion:Ohitinib targeted therapy combined with chemotherapy can effectively improve the short-term and long-term efficacy of advanced non-small cell lung cancer,with certain safety and highclinical application value.

关 键 词：奥希替尼 靶向治疗 晚期非小细胞肺癌 生存期 

分 类 号：R734.2[医药卫生—肿瘤]